What is BURL Concepts?
BURL Concepts operates at the intersection of medical technology and clinical neurology, specifically targeting the assessment of cerebral blood flow. The company's flagship innovation, the SONAS system, represents a paradigm shift in how clinicians approach stroke and neurological trauma. By utilizing a proprietary microbubble solution, the platform provides a rapid, portable, and cost-effective alternative to traditional imaging modalities. This technology is engineered to facilitate real-time monitoring in both acute hospital settings and outpatient environments, effectively bridging the gap between complex diagnostic requirements and the need for accessible, bedside clinical interventions. Despite current regulatory limitations in the United States, the company maintains a robust international profile, positioning itself as a critical player in the global neuro-monitoring landscape.
How much funding has BURL Concepts raised?
BURL Concepts has raised a total of $5.5M across 2 funding rounds:
Series B
$3M
Stock/Share Issuance
$2.5M
Series B (2016): $3M, investors not publicly disclosed
Stock/Share Issuance (2025): $2.5M, investors not publicly disclosed
Key Investors in BURL Concepts
Undisclosed Investor
An institutional investment firm focused on scaling high-impact medical technology companies through strategic capital allocation.
Undisclosed Investor
A specialized venture capital group with a mandate to support early-to-growth stage healthcare innovations and diagnostic platforms.
Undisclosed Investor
A dedicated healthcare-focused investment vehicle providing both financial backing and operational expertise to clinical-stage medical device developers.
What's next for BURL Concepts?
With the infusion of this recent capital, BURL Concepts is well-positioned to accelerate its operational roadmap and expand its clinical footprint. The strategic focus will likely shift toward scaling manufacturing capabilities and navigating the complex regulatory pathways required for broader market entry. As the company matures, the emphasis will remain on refining the SONAS system's diagnostic precision and expanding its utility in post-stroke recovery tracking. Investors are closely monitoring the firm's ability to translate its technological advantages into sustained clinical adoption, particularly as the demand for non-invasive, real-time neurological assessment tools continues to rise globally. Future growth will be predicated on the successful execution of clinical trials and the strategic deployment of resources to penetrate key international healthcare markets.
See full BURL Concepts company page
